Artemis Therapeutics Inc.
ATMS · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $55,792,887 | $55,792,887 | $66,996 | $6,619 |
| - Cash | $1 | $0 | $109 | $55 |
| + Debt | $318 | $0 | $497 | $356 |
| Enterprise Value | $55,793,204 | $55,792,887 | $67,384 | $6,920 |
| Revenue | $176 | $206 | $173 | $116 |
| % Growth | -14.6% | 19.1% | 49.1% | – |
| Gross Profit | $167 | $193 | $144 | $87 |
| % Margin | 94.9% | 93.7% | 83.2% | 75% |
| EBITDA | -$153 | -$273 | -$260 | -$490 |
| % Margin | -86.9% | -132.5% | -150.3% | -422.4% |
| Net Income | $0 | $15 | -$234 | -$518 |
| % Margin | 0% | 7.3% | -135.3% | -446.6% |
| EPS Diluted | 0 | 0 | -0.002 | -0.091 |
| % Growth | -100% | 100% | 97.7% | – |
| Operating Cash Flow | – | – | -$96 | -$41 |
| Capital Expenditures | – | – | $0 | -$18 |
| Free Cash Flow | – | – | -$96 | -$59 |